Company reports $996 million revenue, $2.06 non-GAAP EPS, and maintains full-year targets despite organic revenue decline.
Charles River Laboratories posted Q1 2026 revenue of $996 million, up 1.2% year over year, exceeding its prior outlook. Non-GAAP EPS fell 12% to $2.06 due to margin pressures from NHP costs, stock compensation, and mix issues.
The company reaffirmed full-year guidance for organic revenue to decline 0.5% to 1.5% and non-GAAP EPS of $10.80 to $11.30. It expects 120 to 150 basis points of margin expansion later in the year but adjusted reported revenue outlook downward due to a stronger USD.
New CEO Birgit Girshick outlined a strategic plan, including portfolio reshaping and acquisitions, to sharpen focus and improve profitability. Management emphasized efforts to strengthen NHP supply chain and testing capabilities.